Abstract

Abstract Prostate cancer stands out as the most frequently diagnosed cancer in men and is projected to be the second leading cause of cancer-related deaths among men in the US. Consequently, there is an urgent need for studies focusing on innovative therapeutic approaches. DNA Damage Response (DDR) is critical for cell survival, as it promotes genomic stability and reduces the risk of inheriting damage. DDR also promotes cancer cells' survival, making it a therapeutic target in cancer. PRMT5, an enzyme in the methyltransferase family, is frequently activated and overexpressed in various cancers, including prostate cancer. Furthermore, research has revealed that PRMT5 has been implicated in DDR in prostate cancer, and the regulation of PRMT5-dependent DDR is influenced by its phosphorylation. Polo-like kinase 1 (PLK1) is a serine/threonine kinase also reportedly involved in DDR in prostate cancer. Our preliminary study found that PRMT5 is positively correlated with PLK1 in prostate cancer based on the TCGA database. Nonetheless, the mechanism through which PRMT5 is regulated needs to be clarified. Here, we found that PLK1 phosphorylates PRMT5 at the S470 site, and this specific phosphorylation is required for maintaining the enzymatic activity of PRMT5. Moreover, Plk1-associated phosphorylation of PRMT5 subsequently promotes DNA damage repair, indicated by the decreasing level of γH2AX after DNA double-strand breaks (DSB). Our RNA-seq analyses of prostate cancer cells with wild-type or mutant S470 sites indicate that Plk1-associated phosphorylation on the S470 site exerts an influence on DNA replication and DDR pathways. These findings shed light on a novel perspective regarding the roles of PLK1-mediated PRMT5 phosphorylation in DDR, offering potential therapeutic strategies in prostate cancer. Citation Format: Jia Peng, Yanquan Zhang, Jianlin Wang, Qianjin Li, Daheng He, Xinyi Wang, Xiongjian Rao, Meng Wu, Pingli Mo, Lei Wang, Sai Wu, Ruixin Wang, Jinghui Liu, Mansoureh Nouri, Izumi Tadahide, Xiaoqi Liu. PLK1-dependent phosphorylation of PRMT5 promotes DNA damage response in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6014.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call